KRAS and non-small cell lung carcinoma: For instance, KRAS-mutated pancreatic cancer results in the upregulation and activation of NRF2 (NFE2L), a master regulator of the antioxidant network resulting in the metabolically rewiring and elevation of the pathways involved in glutamine metabolism [100] and a key pathway in NSCLC alongside its negative regulator KEAP1 [30,101].